CBD Pre-Conference Workshop

Course Description

Numerous physical, psychological, and emotional benefits have been attributed to marijuana since its first reported use in approximately 2,600 BC in Chinese pharmacopoeias. Since the adoption of the Uniform State Narcotic Act in 1932, research and clinical use of marijuana in the U.S. had been limited primarily to animal studies and human case reports on the phytocannabinoids found in both marijuana and hemp.

In 1986, there were 8 articles listed in PubMed under the topic "medical marijuana"; in 2016, over 500 were published: a 6,000% increase. The phytocannabinoids, cannabidiol (CBD), and delta-9-tetrahydrocannabinol (Δ9-THC), are currently the most studied extracts from the plant species cannabis sativa. Both hemp and marijuana are subspecies of cannabis sativa and are bred separately, with each having various amounts of CBD and Δ9-THC. Both CBD and Δ9-THC interact uniquely with the endocannabinoid system (ECS). Through both direct and indirect actions, endocannabinoids modulate and influence a variety of physiological systems, including appetite, pain, inflammation, thermoregulation, intra-ocular pressure, sensation, muscle control, energy balance, metabolism, sleep health, stress responses, motivation/reward, mood, and memory.

Research into the neurological benefits of both CBD and Δ9-THC has demonstrated numerous neuroprotective effects against excessive oxidative stress and inflammation associated with a variety of neurological diseases and conditions. These include malignant brain tumors, Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, neuropathic pain, and the childhood seizure disorders Lennox-Gastaut and Dravet Syndromes. In addition, psychiatric and mood disorders such as schizophrenia, anxiety, depression, addiction, post-concussion syndrome, and post-traumatic stress disorders are being studied and treated with phytocannabinoids.

Due to the explosion of societal, political and legislative changes in the United States, medical marijuana has been legalized in 29 states since 1996--the majority within the last 5 years. The large numbers of healthcare providers in these states have little, if any, formal education or training about condition-specific recommendations, dosing concerns, side effects, and drug interactions. This workshop is designed to help educate prescribers on a wide variety of medical marijuana related topics based on the latest scientific and clinical research.

University of Washington School of Medicine

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Washington School of Medicine and A4M. The University of Washington School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Washington School of Medicine designates this live activity for a maximum of 7 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.





Learning Objectives

  • Discuss the history of Endocannabinoid System discovery, both intrinsic and extrinsic activators, receptors and interactions with various organ systems in the body.
  • Understand how the undying actions and functions or the Endocannabinoid System interacts with various conditions and diseases and the use of medical marijuana and cannabidiol (CBD).
  • Review the use of cannabis and cannabinoids for managing symptoms related to cancer pain and non-cancer pain.
  • Discuss early research on cannabinoids direct anti-tumor activity, especially within the central nervous system.
  • Provide animal and human research data on the current clinical neurological uses for CBD.
  • Emphasize the neuroprotective, anti-inflammatory, and immunomodulatory benefits of phytocannabinoids and their applications in various neurological clinical syndromes.
  • Focus on various psychological benefits of CBD and the latest information of stress reduction and sexual function.
  • Therapeutic applications of CBD such as analgesic, anti-inflammatory and as an anxiolytic without psychoactive effects.
  • Discuss evidence surrounding cannabis use to reduce neural damage and improve recovery following a brain injury.

Event Schedule

Wednesday, December 12, 2018

8:45 AM

Introductions (non-CME)

Joseph Maroon, MD, FACS

9:00 AM

The Endocannabinoid System

Hector Lopez, MD

10:00 AM


10:30 AM

Treatment Applications for Neurological and Head Trauma with Cannabis and Cannabinoids

Michael Lewis, MD

11:30 AM

The Role of Medical Marijuana and CBD for Cancer and Pain

Joseph Maroon, MD, FACS

12:30 PM


1:30 PM

Stress, Adrenal Health, and Cannabidiol: The ECS-HPA Connection

Aimée Gould Shunney, ND

2:30 PM

Exploring Medical Marijuana: Cannabidiol (CBD) for Diabetes and Diabetic Complications

Jeff Bost, PAC

3:30 PM


4:00 PM

Medical Cannabis Dosing and Administration

Jamie Corroon, ND, MPH

5:00 PM

Cannabis in the Toolkit for Opioids Tapering: A Protocol and Potential Pitfalls

Michelle Sexton, ND

6:00 PM

Close on Session

Register Today!



3355 S Las Vegas Blvd
Las Vegas, NV 89109, US
(702) 607-7777

Rm Rate: $215/night
While Rooms are Available
Group Code – RAGNG

A4M World Congress 2018 - The Ventian and Palazzo Resort

Save on your airfare by flying with Delta Airlines. Mention Code NMR6W and receive anywhere from a 3%-10% discount depending on class.

ADD EVENT TO MY CALENDAR 12/14/2018 07:00 AM 12/15/2018 06:00 PM America/New_York A4M World Congress 2018 Las Vegas, NV

Contact Us Today!

Contact Me About: